BRIEF published on 04/15/2026 at 17:50, 4 months 27 days ago Mauna Kea Technologies to experience strong growth in Q1 2026 Revenue Growth Medical Technologies Cellvizio Food Intolerances
BRIEF published on 04/15/2026 at 17:50, 4 months 27 days ago Mauna Kea Technologies en forte croissance au T1 2026 Chiffre D'affaires Croissance Cellvizio Technologies Médicales Intolérances Alimentaires
PRESS RELEASE published on 04/15/2026 at 17:45, 4 months 27 days ago Informations privilégiées / Autres communiqués Mauna Kea Technologies annonce une forte croissance de ses ventes au T1 2026, avec des ventes totales en hausse de +68% à taux de change constant (TCC) et +57% en publié Croissance Ventes Mauna Kea Technologies CellTolerance T1 2026
BRIEF published on 03/11/2026 at 17:50, 6 months 1 day ago Mauna Kea Technologies Achieves Milestone with CLIMB Study Mauna Kea Technologies Cellvizio Pancreatic Cysts CLIMB Study ASGE Plenary Session
BRIEF published on 03/11/2026 at 17:50, 6 months 1 day ago Mauna Kea Technologies franchit une étape importante avec l'étude CLIMB Mauna Kea Technologies Cellvizio Kystes Pancréatiques Étude CLIMB Session Plénière De L'ASGE
PRESS RELEASE published on 03/11/2026 at 17:45, 6 months 1 day ago Inside Information / Other news releases Mauna Kea Technologies announces CLIMB study for Cellvizio® in Pancreatic Cysts selected for ASGE Presidential Plenary Session at DDW 2026, showcasing superior diagnostic accuracy and clinical impact Mauna Kea Technologies Cellvizio Pancreatic Cysts CLIMB Study ASGE
BRIEF published on 02/10/2026 at 17:50, 7 months 2 days ago Mauna Kea Technologies Secures CE MDR Certification for Cellvizio® Cellvizio Clinical Expansion CE MDR Certification European Commercialization MedTech Regulation
BRIEF published on 02/10/2026 at 17:50, 7 months 2 days ago Mauna Kea Technologies obtient la certification CE MDR pour Cellvizio® Cellvizio Expansion Clinique Certification CE MDR Commercialisation Européenne Réglementation Des Technologies Médicales
PRESS RELEASE published on 02/10/2026 at 17:45, 7 months 2 days ago Inside Information / Other news releases Mauna Kea Technologies announces CE MDR certification for Cellvizio and probes, marking a key milestone in their European expansion strategy under new regulation Mauna Kea Technologies Cellvizio Regulatory Milestone CE MDR Certification European Expansion Strategy
BRIEF published on 01/21/2026 at 17:50, 7 months 22 days ago Mauna Kea Technologies : Agenda financier 2026 dévoilé Calendrier Financier Conférences Investisseurs Mauna Kea Technologies Cellvizio Stratégies De Croissance
Published on 09/12/2026 at 02:35, 1 day 10 hours ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 1 day 13 hours ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 21:25, 1 day 15 hours ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 1 day 19 hours ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 17:50, 18 hours 50 minutes ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 1 day 5 hours ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 1 day 14 hours ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 1 day 14 hours ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 1 day 16 hours ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 07:00, 2 days 5 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 2 days 5 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 2 days 17 hours ago Availability of the 2026 Interim Financial Report
